Details of the Drug

General Information of Drug (ID: DMEBOFW)

• Drug Name: Clofazimine
• Synonyms: clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Leprosy	N.A.	Approved	[2]
Multibacillary leprosy	N.A.	Approved	[2]
Pyoderma gangrenosum	EB21	Approved	[2]
Mycobacterium infection	1B10-1B21	Investigative	[3]

• Therapeutic Class: Antiinflammatory Agents
• Affected Organisms: MycobacteriaMycobacterium leprae
• ATC Code:
  J04BA01: Clofazimine
  J04BA: Drugs for treatment of lepra
  J04B: DRUGS FOR TREATMENT OF LEPRA
  J04: ANTIMYCOBACTERIALS
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 473.4
  Logarithm of the Partition Coefficient (xlogp); 7.1
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.41 mg/L [4]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 8 h [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
  Bioavailability: 57% of drug becomes completely available to its intended biological destination(s) [6]
  Elimination: 0.2% of drug is excreted from urine in the unchanged form [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 25 days [4]
  Metabolism: The drug is metabolized via a hydrolytic deamination reaction followed by glucuronidation [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.03408 micromolar/kg/day [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.001 mg/mL [5]
• Chemical Identifiers:
  Formula: C27H22Cl2N4
  IUPAC Name: N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
  Canonical SMILES: CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
  InChI: InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
  InChIKey: WDQPAMHFFCXSNU-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2794
  ChEBI ID: CHEBI:3749
  CAS Number: 2030-63-9
  UNII: D959AE5USF
  DrugBank ID: DB00845
  TTD ID: D0S5UH
  VARIDT ID: DR00669
  INTEDE ID: DR0346
  ACDINA ID: D00956
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Deoxyribonucleic acid (Bact DNA)	TTS1W4A	NOUNIPROTAC	Modulator	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[11]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[12]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clofazimine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[13]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Midostaurin.	Acute myeloid leukaemia [2A60]	[14]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Idarubicin.	Acute myeloid leukaemia [2A60]	[14]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Arn-509.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Oliceridine.	Acute pain [MG31]	[14]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Rivastigmine.	Alzheimer disease [8A20]	[16]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Clofazimine and Metronidazole.	Amoebiasis [1A36]	[17]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ivabradine.	Angina pectoris [BA40]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Bepridil.	Angina pectoris [BA40]	[16]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Dronedarone.	Angina pectoris [BA40]	[16]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Cilostazol.	Arterial occlusive disease [BD40]	[14]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Posaconazole.	Aspergillosis [1F20]	[14]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Levalbuterol.	Asthma [CA23]	[19]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Terbutaline.	Asthma [CA23]	[20]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Pirbuterol.	Asthma [CA23]	[19]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Salbutamol.	Asthma [CA23]	[19]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Formoterol.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[15]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Clofazimine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Retigabine.	Behcet disease [4A62]	[14]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Eribulin.	Breast cancer [2C60-2C6Y]	[14]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lapatinib.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Bosutinib.	Breast cancer [2C60-2C6Y]	[14]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[14]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Isoproterenol.	Conduction disorder [BC63]	[19]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Halothane.	Corneal disease [9A76-9A78]	[14]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Sevoflurane.	Corneal disease [9A76-9A78]	[14]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Probucol.	Coronary atherosclerosis [BA80]	[14]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Pasireotide.	Cushing syndrome [5A70]	[16]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Osilodrostat.	Cushing syndrome [5A70]	[14]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Escitalopram.	Depression [6A70-6A7Z]	[16]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Clomipramine.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Doxepin.	Depression [6A70-6A7Z]	[14]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Maprotiline.	Depression [6A70-6A7Z]	[14]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[16]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Ingrezza.	Dystonic disorder [8A02]	[22]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Solifenacin.	Functional bladder disorder [GC50]	[14]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Ketoconazole.	Fungal infection [1F29-1F2F]	[14]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[14]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Clofazimine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Crizotinib.	Lung cancer [2C25]	[24]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Ceritinib.	Lung cancer [2C25]	[16]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Osimertinib.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Selpercatinib.	Lung cancer [2C25]	[26]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Lumefantrine.	Malaria [1F40-1F45]	[17]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Halofantrine.	Malaria [1F40-1F45]	[17]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Hydroxychloroquine.	Malaria [1F40-1F45]	[27]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Primaquine.	Malaria [1F40-1F45]	[14]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[14]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[28]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Vemurafenib.	Melanoma [2C30]	[16]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and LGX818.	Melanoma [2C30]	[29]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Panobinostat.	Multiple myeloma [2A83]	[30]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Thalidomide.	Multiple myeloma [2A83]	[17]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Fingolimod.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ozanimod.	Multiple sclerosis [8A40]	[31]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Romidepsin.	Mycosis fungoides [2B01]	[14]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[14]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Promethazine.	Nausea/vomiting [MD90]	[14]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Granisetron.	Nausea/vomiting [MD90]	[14]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Ondansetron.	Nausea/vomiting [MD90]	[14]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Entrectinib.	Non-small cell lung cancer [2C25]	[14]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lofexidine.	Opioid use disorder [6C43]	[16]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Rucaparib.	Ovarian cancer [2C73]	[14]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Buprenorphine.	Pain [MG30-MG3Z]	[14]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Triclabendazole.	Parasitic worm infestation [1F90]	[14]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Pimavanserin.	Parkinsonism [8A00]	[32]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Famotidine.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[33]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Lefamulin.	Pneumonia [CA40]	[13]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ritodrine.	Preterm labour/delivery [JB00]	[19]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Degarelix.	Prostate cancer [2C82]	[15]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and ABIRATERONE.	Prostate cancer [2C82]	[15]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Enzalutamide.	Prostate cancer [2C82]	[15]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Relugolix.	Prostate cancer [2C82]	[15]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Bicalutamide.	Prostate cancer [2C82]	[15]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[14]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[34]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Quetiapine.	Schizophrenia [6A20]	[16]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Mesoridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Paliperidone.	Schizophrenia [6A20]	[14]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Perphenazine.	Schizophrenia [6A20]	[14]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Amisulpride.	Schizophrenia [6A20]	[35]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Asenapine.	Schizophrenia [6A20]	[16]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Pimozide.	Schizophrenia [6A20]	[15]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[14]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[16]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Pitolisant.	Somnolence [MG42]	[14]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[14]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Lenvatinib.	Thyroid cancer [2D10]	[14]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Cabozantinib.	Thyroid cancer [2D10]	[15]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Papaverine.	Tonus and reflex abnormality [MB47]	[36]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Tacrolimus.	Transplant rejection [NE84]	[14]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[14]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[16]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[14]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Clofazimine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[14]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Clofazimine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Butylated hydroxytoluene	E00336	31404	Antioxidant
Ethyl vanillin	E00178	8467	Flavoring agent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
methylparaben	E00149	7456	Antimicrobial preservative
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Ethylparaben	E00177	8434	Antimicrobial preservative
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Soybean lecithin	E00637	Not Available	Other agent
Haematite red	E00236	14833	Colorant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clofazimine 100mg capsule	100mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019500.
• [2] Clofazimine FDA Label
• [3] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [4] FDA Approved Drug Products: Lamprene (clofazimine) oral capsules
• [5] BDDCS applied to over 900 drugs
• [6] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
• [9] Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
• [10] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [11] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [12] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [13] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [14] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [15] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [16] Canadian Pharmacists Association.
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [20] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [21] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
• [22] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [23] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [24] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [25] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [26] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [27] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [28] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [29] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [30] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [31] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [32] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [33] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [34] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [35] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [36] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]